Axona® (Accera, Inc): A new medical food therapy for persons with Alzheimer's disease

Issues in Mental Health Nursing

Volumn 31, Issue 6, 2010, Pages 435-436

  Roman, Marian W ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETONE BODY;

ALZHEIMER DISEASE; ARTICLE; DIET SUPPLEMENTATION; DIET THERAPY; FOOD AND DRUG ADMINISTRATION; FOOD CONTROL; HEALTH CARE POLICY; HUMAN; METABOLISM; UNITED STATES;

ALZHEIMER DISEASE; DIETARY SUPPLEMENTS; FOOD INSPECTION; HUMANS; KETONE BODIES; NUTRITION POLICY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952212079     PISSN: 01612840     EISSN: 10964673     Source Type: Journal    
DOI: 10.3109/01612841003768231     Document Type: Article

References (6)

1. Accera. (2009). Retrieved April 1, 2009, from http://www.accerapharma. com/2009/news34.html. Axona Product Bulletin. Retrieved April 1, 2009, from http://www. firstreportnow.com/ProductBulletiGeriatricACCERA.pdf
2. de Leon, M. J., Ferris, S. H., George, A. E., Christman, D. R., Fowler, J.S., Gentes, C., et al. (1983). Positron emission tomographic studies of aging and Alzheimer's disease. American Journal of Neuroradiology, 4(3), 568-571.
3. Henderson, S. T., Vogel, J. L., Barr, L. J., Garvin, F., Jones, J. J., & Costantini, L. C. (2009, August 10). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled,multicenter trial. RetrievedMarch 5, 2010, from Nutrition & Metabolism (London) [online]. doi: 10.1186/1743-7075-6-31. PMCID: PMC2731764.
4. Herholz, K., Carter, S. F., & Jones, M. (2007). Positron emission tomography imaging in dementia. British Journal of Radiology, 80(Special issue 2), S160-S167.
5. Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. European Journal of Nuclear Medicine and Nuclear Imaging, 32(4), 486-510.
6. Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y. et al. (2009). FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging, 36(5), 811-822.